Table 3.
Number and percentage of eyes with subclinical CI-DMO and CI-DMO by ETDRS group at baseline (V1) and at the 3-year follow-up visit (V4) and respective LOR fluctuations and BCVA variations.
| Subclinical CI-DMO (CRT ≥ 1 SD and <2SD) | CI-DMO (CRT ≥ 2 SD) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ETDRS 10–20 | ETDRS 35 | ETDRS 43–47 | ETDRS 10-20 | ETDRS 35 | ETDRS 43–47 | ||||
| Baseline (V1) | 9/23 (39%) | 10/31 (32%) | 6/20 (30%) | 2/23 (9%) | 3/31 (10%) | 3/20 (15.0%) | |||
| 3-year Visit (V4) | 6/23 (26%) | 10/31 (32%) | 8/20 (40%) | 2/23 (9%) | 2/31 (7%) | 2/20 (10.0%) | |||
| Number of eyes with increased LOR ratio (≥1SD) | |||||||||
| Subclinical CI-DMO | CI-DMO | ||||||||
| ETDRS 10–20 | ETDRS 35 | ETDRS 43–47 | ETDRS 10–20 | ETDRS 35 | ETDRS 43–47 | ||||
| Baseline (V1) | 2/9 (22%) | 4/10 (40%) | 3/6 (50%) | 1/2 (50%) | 1/3 (33%) | 1/3 (33%) | |||
| 3-year Visit (V4) | 3/6 (50%) | 7/10 (70%) | 7/8 (88%) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | |||
| LOR fluctuations and BCVA variations over the follow-up period of subclinical CI-DMO or CI-DMO eyes | |||||||||
| Vision Gain | No Vision Change | Vision Loss | |||||||
| Without LOR fluctuations | 8 (67%) | 2 (29%) | 2 (18%) | ||||||
| With LOR fluctuations | 4 (33%) | 5 (71%) | 9 (82%) | ||||||
| 12 | 7 | 11 | |||||||
CI-DMO centre-involving diabetic macular oedema, CRT central retinal thickness, SD standard deviation, LOR low optical reflectivity, BCVA best-corrected visual acuity.